- Home
- GILD vs REGN Comparison
GILD vs REGN Comparison
Compare GILD & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- REGN
- Stock Information
- Founded
- GILD 1987
- REGN 1988
- Country
- GILD United States
- REGN United States
- Employees
- GILD N/A
- REGN N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- GILD Health Care
- REGN Health Care
- Exchange
- GILD Nasdaq
- REGN Nasdaq
- Market Cap
- GILD 113.0B
- REGN 110.0B
- IPO Year
- GILD 1992
- REGN 1991
- Fundamental
- Price
- GILD $93.94
- REGN $713.73
- Analyst Decision
- GILD Buy
- REGN Buy
- Analyst Count
- GILD 26
- REGN 24
- Target Price
- GILD $96.71
- REGN $1,054.00
- AVG Volume (30 Days)
- GILD 7.2M
- REGN 872.0K
- Earning Date
- GILD 02-11-2025
- REGN 01-31-2025
- Dividend Yield
- GILD 3.28%
- REGN N/A
- EPS Growth
- GILD N/A
- REGN 15.31
- EPS
- GILD 0.10
- REGN 40.43
- Revenue
- GILD $28,299,000,000.00
- REGN $13,847,100,000.00
- Revenue This Year
- GILD $6.50
- REGN $10.20
- Revenue Next Year
- GILD $0.36
- REGN $4.16
- P/E Ratio
- GILD $929.26
- REGN $17.67
- Revenue Growth
- GILD 3.31
- REGN 5.72
- 52 Week Low
- GILD $62.07
- REGN $693.00
- 52 Week High
- GILD $98.90
- REGN $1,211.20
- Technical
- Relative Strength Index (RSI)
- GILD 57.65
- REGN 33.59
- Support Level
- GILD $90.27
- REGN $706.15
- Resistance Level
- GILD $94.05
- REGN $720.00
- Average True Range (ATR)
- GILD 1.99
- REGN 19.84
- MACD
- GILD 0.07
- REGN 1.53
- Stochastic Oscillator
- GILD 82.30
- REGN 19.68
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).